Combination drug therapies for AD: progress is slow, but we must keep trying.
Farlow
Martin R
MR
D000544:Alzheimer Disease / Q000188:drug therapy*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D000077265:Donepezil; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007189:Indans / Q000627:therapeutic use; D008559:Memantine / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D004967:Estrogens; D018691:Excitatory Amino Acid Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil; D008559:Memantine